Clinical trials: Thromboembolus
Hepatitis C
WEUSKOP5410: Observational Study in ENABLE Clinical Trials
Hepatitis C Virus (HCV) is a leading cause of chronic liver disease (CLD) worldwide. Current mainstay of treatment is combination therapy with pegylated interferon and ribavarin.
- Trial name
- NCT01458080
- Testing
- eltrombopag
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Venous Thromboembolism, Pulmonary Embolism
Exclusion of Venous Thrombo-Embolism With a New Clinical Decision Support
The goal of this non interventional study is to demonstrate the diagnostic performances on fresh plasmas in comparison with the performances on frozen plasmas in any patients with VTE suspicion, whatever the pre-test probability.
- Conditions
- Venous Thromboembolism, Pulmonary Embolism, Deep Vein Thrombosis
- Trial name
- EXTEND (NCT06480994)
- Testing
- Routine Assays on fresh plasma, New Clinical Decision Support on fresh plasma, New Clinical Decision Support on frozen plasma
- Where
- 4 sites in France
- Volunteers
- 1,836 people
- Sponsor
- Diagnostica Stago R&D
Thromboembolism, Heart Valve Prosthesis
Follow on Study From RE-ALIGN
To collect additional data relating to safety and indicators of efficacy for patients who have participated in the 1160.113 study.
- Trial name
- NCT01505881
- Testing
- dabigatran etexilate low dose, warfarin 5mg, dabigatran etexilate intermediate dose
- Where
- 30 sites in Belgium, Canada and 7 more
- Volunteers
- 158 people
- Sponsor
- Boehringer Ingelheim
Deep Vein Thrombosis, Venous Thrombosis
Treatment of an Acute Deep Vein Thrombosis (DVT) With Either Rivaroxaban or Current Standard of Care Therapy
Following the findings of the clinical trials in drug development, this global non-interventional cohort field study will investigate rivaroxaban under clinical practice conditions in comparison with current standard of care for…
- Trial name
- XALIA (NCT01619007)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Standard of care
- Where
- 21 sites in Austria, Belgium and 19 more
- Volunteers
- 5,145 people
- Sponsor
- Bayer
Venous Thrombosis
Venous Thromboembolism Taskforce Audit Program
To determine the effect of an interventional campaign run by a dedicated "VTE Nurse Educator" over a 6-month period and the effect on prophylaxis rates.
- Trial name
- NCT00535171
- Where
- Australia
- Volunteers
- 8,764 people
- Sponsor
- Sanofi
Prevention of Venous Thromboembolism, Congenital Heart Disease
An Observational Study to Learn More About How Safe Rivaroxaban is And How Well it Works in Children With Congenital Heart Disease Who Had a Heart Surgery Called the Fontan Procedure
This is an observational study in which the data from children with congenital heart disease will be collected and studied. These children will include those who are prescribed rivaroxaban by their doctors after a heart surgery…
- Conditions
- Prevention of Venous Thromboembolism, Congenital Heart Disease, Fontan Procedure, Children
- Trial name
- NCT06193863
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- Japan
- Volunteers
- 61 people
- Sponsor
- Bayer
Venous Thromboembolism
Open Label Study Comparing Efficacy and Safety of Dabigatran Etexilate to Standard of Care in Paediatric Patients With Venous Thromboembolism (VTE)
The main objectives of this large phase IIb/III paediatric study are to assess the efficacy and safety of dabigatran etexilate relative to standard of care and to document the appropriateness of the proposed dabigatran etexilate…
- Trial name
- NCT01895777
- Testing
- dabigatran etexilate, standard of care
- Where
- 65 sites in United States, Argentina and 24 more
- Volunteers
- 267 people
- Sponsor
- Boehringer Ingelheim
Prevention of Arterial and Venous Thrombosis
A Clinical Study of SHR-2004 Injection in Preventing Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty
The purpose of the study is to evaluate the efficacy and safety of SHR-2004 in preventing venous thromboembolism after elective unilateral total knee arthroplasty.
- Trial name
- NCT06825416
- Testing
- SHR-2004 injection, Enoxaparin sodium injection
- Where
- 2 sites in China
- Volunteers
- 1,165 people
- Sponsor
- Beijing Suncadia Pharmaceuticals Co., Ltd
Venous Thromboembolism
An Observational Study on Incidence, Natural History and Treatment Patterns of Venous Thromboembolism in Taiwan
The research question addressed by this study is primarily on the clinical epidemiology of VTE in Taiwan. The study aims to estimate the incidence of VTE and describe natural history of VTE, including long term clinical outcomes…
- Trial name
- NCT03799016
- Where
- Taiwan
- Volunteers
- 104,215 people
- Sponsor
- Bayer
Multiple Myeloma
A Safety and Efficacy of Pomalyst® Capsules Under the Actual Use in All Patients Who Are Treated With Pomalyst at a Dose of 1 mg, 2 mg, 3 mg, or 4 mg
1. Planned enrollment period One year (The planned number of patients to be enrolled is set to 400 patients.) Since all patients who are prescribed with Pomalyst are registered in RevMate®, enrollment using the Registration Form…
- Trial name
- NCT02921828
- Where
- 2 sites in United States, Japan
- Volunteers
- 1,149 people
- Sponsor
- Celgene
Thromboembolic Event, FDP
Safety And Field Evaluation of Plasma Lyophilized for Acute and Surgical Management Applications
The purpose of this study is to compare the safety of freeze-dried plasma (FDP), known as EZPLAZ, with conventional plasma in adults who need a plasma transfusion.
- Trial name
- SAFE-PLASMA (NCT07840352)
- Testing
- Freeze-Dried Plasma, Conventional Plasma
- Volunteers
- 867 people
- Sponsor
- Teleflex
Non Valvular Atrial Fibrillation
Apixaban Versus Rivaroxaban in Non Valvular Atrial Fibrillation
The investigators will first measure the maximum concentration (after 2 hours of intake) and the residual concentration (just before the next intake) after at least 15 consecutive days of treatment.
- Trial name
- APIXA-Xa (NCT06862726)
- Testing
- Anti Xa dosage, Dosage of PT-INR
- Where
- Tunisia
- Volunteers
- 120 people
- Sponsor
- Les Laboratoires des Médicaments Stériles
Venous Thromboembolism
Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 12 Years of Age
To investigate the safety and tolerability of dabigatran etexilate solution in children and to obtain preliminary pharmacokinetic/pharmacodynamic data
- Trial name
- NCT01083732
- Testing
- dabigatran etexilate
- Where
- 7 sites in Canada, Italy and 4 more
- Volunteers
- 18 people
- Sponsor
- Boehringer Ingelheim
Thrombosis, Venous
Total Hip Replacement Study Of GSK576428 (Fondaparinux Sodium)
This study is requested by PMDA to confirm the optimal dose for THR (total hip replacement).
- Trial name
- NCT00320398
- Testing
- Fondaparinux
- Volunteers
- 114 people
- Sponsor
- GlaxoSmithKline
Atrial Fibrillation, Thromboembolism
AMPLATZER™ LAA Occluder Post Approval Study (PAS)
The aim of this multicenter, non-randomized observational post-approval is to compile real world outcome data on the use of an AMPLATZER LAA Occluder in subjects with non-valvular atrial fibrillation (NVAF).
- Conditions
- Atrial Fibrillation, Thromboembolism, Stroke
- Trial name
- NCT02964208
- Testing
- AMPLATZER™ LAA Occluder
- Where
- 22 sites in Argentina, Belgium and 5 more
- Volunteers
- 520 people
- Sponsor
- Abbott Medical Devices
Deep Vein Thrombosis (DVT), Thrombus in the Peripheral Venous Vasculature
Cleaner Long-tErm Assessment Registry - Venous Insights and Efficacy With eXtended Tracking
The primary objective of this clinical investigation is to evaluate the safety and effectiveness of the Cleaner Vac® Thrombectomy System for the treatment of thrombus in patients with lower extremity proximal deep vein thrombosis…
- Conditions
- Deep Vein Thrombosis (DVT), Thrombus in the Peripheral Venous Vasculature, Venous Embolism, Thrombus in the Central and Peripheral Circulatory System, Including Saphenous Vein Grafts
- Trial name
- CLEAR-VIEW XT (NCT07102160)
- Testing
- Aspiration thrombectomy system
- Where
- 4 sites in United States
- Volunteers
- 185 people
- Sponsor
- Argon Medical Devices
Circulatory Disease
Phase II Clinical Study of H001 Capsule in the Prevention of Venous Thromboembolism After Total Knee Arthroplasty
This study is a multicenter, randomized, open-label, positive-controlled Phase II clinical study to evaluate the efficacy and safety of H001 capsules in the prevention of venous thromboembolism (VTE) in subjects undergoing Total…
- Trial name
- NCT06963320
- Testing
- H001 Capsule 200mg-qd, Enoxaparin Sodium Injection, H001 Capsule 300mg-qd
- Where
- China
- Volunteers
- 320 people
- Sponsor
- Livzon Pharmaceutical Group Inc.
Venous Thromboembolism
Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Elective Knee Replacement Surgery
The primary objective was to compare the efficacy of Semuloparin sodium (AVE5026) with Enoxaparin for the prevention of Venous Thromboembolic Events [VTE] in patients undergoing elective knee replacement surgery.
- Trial name
- SAVE-KNEE (NCT00718224)
- Testing
- Semuloparin sodium, Enoxaparin
- Where
- 17 sites in United States, Argentina and 15 more
- Volunteers
- 1,150 people
- Sponsor
- Sanofi
Venous Thromboembolism
An Observational Study On The Safety And Tolerability Of Prolonged Thrombosis Prophylaxis With Fragmin®
The objective of this study is to observe the safety, tolerability, and compliance in the use of Fragmin® for prolonged thromboprophylaxis in post-surgery high-risk orthopedic patients.
- Trial name
- NCT01046903
- Testing
- Fragmin® (Dalteparin Sodium)
- Volunteers
- 503 people
- Sponsor
- Pfizer
Thromboembolism, Prevention
ODiXahip - a Phase IIa Dose Escalating Proof of Principle Trial
Patients undergoing surgery, especially hip and knee surgery, are at high risk for VTE (up to 60 % without prophylaxis). The administration of drugs for thromboprophylaxis, such as heparins, significantly lowers that risk, but…
- Trial name
- ODiXaHip (NCT00839826)
- Testing
- Rivaroxaban (BAY59-7939), Enoxaparin
- Where
- 41 sites in Austria, Belgium and 9 more
- Volunteers
- 641 people
- Sponsor
- Bayer